Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q2 FY21 results · Jul–Sep 2020
Astec LifeSciences reported revenue from operations of ₹155.00 crore (up 10.5% from Q2 FY20) and net profit of ₹17.85 crore (up 237.7% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 155.00 | 140.21 | +10.5% | 111.94 | +38.5% |
| Other income | 1.85 | 1.82 | +1.3% | 1.25 | +47.1% |
| Total income | 156.85 | 142.04 | +10.4% | 113.20 | +38.6% |
| Profit before tax | 23.88 | 7.83 | +205.0% | 21.74 | +9.9% |
| Net profit for the period | 17.85 | 5.29 | +237.7% | 16.19 | +10.3% |
| EPS, basic (₹) | 9.12 | 2.70 | +237.8% | 8.27 | +10.3% |
| Net margin (%) | 11.5 | 3.8 | 14.5 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 155.00 | 140.21 | +10.5% | 111.94 | +38.5% |
| Other income | 1.59 | 1.82 | −12.4% | 1.25 | +27.1% |
| Total income | 156.60 | 142.04 | +10.3% | 113.20 | +38.3% |
| Profit before tax | 23.55 | 7.81 | +201.6% | 21.72 | +8.4% |
| Net profit for the period | 17.53 | 5.27 | +232.5% | 16.17 | +8.4% |
| EPS, basic (₹) | 8.96 | 2.70 | +231.9% | 8.26 | +8.5% |
| Net margin (%) | 11.3 | 3.8 | 14.4 |
Consolidated
- Filed with BSE
- 03 Nov 2020, 14:44 IST
- Board meeting
- 29 Oct 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 03 Nov 2020, 14:44 IST
- Board meeting
- 29 Oct 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE